MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc has a research collaboration and evaluation agreement with Janssen Pharmaceuticals, Inc. the company was founded in 2015 and is based in New York, New York.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646-490-2965
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees59
Next Earnings Date2/28/2019 (Estimated)
OptionableNot Optionable
MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions
What is MeiraGTx's stock symbol?
MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."
How were MeiraGTx's earnings last quarter?
MeiraGTx Holdings PLC (NASDAQ:MGTX) announced its earnings results on Thursday, November, 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.01. View MeiraGTx's Earnings History.
When is MeiraGTx's next earnings date?
What price target have analysts set for MGTX?
4 brokers have issued 12 month price objectives for MeiraGTx's stock. Their forecasts range from $20.00 to $30.00. On average, they expect MeiraGTx's share price to reach $23.6667 in the next twelve months. This suggests a possible upside of 85.5% from the stock's current price. View Analyst Price Targets for MeiraGTx.
What is the consensus analysts' recommendation for MeiraGTx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MeiraGTx.
What are Wall Street analysts saying about MeiraGTx stock?
Here are some recent quotes from research analysts about MeiraGTx stock:
- 1. Chardan Capital analysts commented, "We note this is Meira’s 2nd collaboration with Janssen, the 1st of which was announced on 16 October 2018, and covers Meira’s riboswitch technology, which is particularly relevant for mass market indications." (1/31/2019)
- 2. According to Zacks Investment Research, "MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. " (1/2/2019)
Has MeiraGTx been receiving favorable news coverage?
News headlines about MGTX stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MeiraGTx earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of MeiraGTx's key competitors?
Some companies that are related to MeiraGTx include Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA), Autolus Therapeutics (AUTL), Audentes Therapeutics (BOLD), Rubius Therapeutics (RUBY), Coherus Biosciences (CHRS), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Vericel (VCEL), BAVARIAN NORDIC/S (BVNRY), Heska (HSKA), Novavax (NVAX) and NanoString Technologies (NSTG).
What other stocks do shareholders of MeiraGTx own?
Who are MeiraGTx's key executives?
MeiraGTx's management team includes the folowing people:
- Dr. Alexandria Forbes, CEO, Pres & Director (Age 54)
- Mr. Richard Brian Giroux, Chief Operating Officer (Age 47)
- Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 56)
- Ms. Katherine Edna Breedis C.F.A., CFA, CMT, Chief Financial Officer
- Prof. Gregory A. Petsko, Chief Scientist & Chairman of Scientific Advisory Board
When did MeiraGTx IPO?
(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.
Who are MeiraGTx's major shareholders?
MeiraGTx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (1.72%), BlackRock Inc. (0.65%), AE Wealth Management LLC (0.39%), IFP Advisors Inc (0.27%), Sphera Funds Management LTD. (0.26%) and Northern Trust Corp (0.15%). View Institutional Ownership Trends for MeiraGTx.
Which institutional investors are buying MeiraGTx stock?
MGTX stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, AE Wealth Management LLC, IFP Advisors Inc, Sphera Funds Management LTD., BlackRock Inc., SG Americas Securities LLC, Northern Trust Corp and Geode Capital Management LLC. View Insider Buying and Selling for MeiraGTx.
How do I buy shares of MeiraGTx?
Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MeiraGTx's stock price today?
One share of MGTX stock can currently be purchased for approximately $12.76.
How big of a company is MeiraGTx?
MeiraGTx has a market capitalization of $349.46 million. MeiraGTx employs 59 workers across the globe.
What is MeiraGTx's official website?
How can I contact MeiraGTx?
MeiraGTx's mailing address is 430 EAST 29TH STREET 10TH FLOOR, NEW YORK NY, 10016. The company can be reached via phone at 646-490-2965 or via email at [email protected]
MarketBeat Community Rating for MeiraGTx (NASDAQ MGTX)
MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote "Outperform" if you believe MGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
